Re­ju­ve­nate Bio shrinks staff, pipeline fo­cus as George Church spin­out eyes 2024 gene ther­a­py IND

Like many oth­er biotechs in this mar­ket en­vi­ron­ment, small gene ther­a­py mak­er Re­ju­ve­nate Bio has strug­gled to re­ju­ve­nate its bank ac­count.

The San Diego start­up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER